Publications

Department of Medicine faculty members published more than 3,600 peer-reviewed articles in 2024.

Filter by

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Effects of potent antiretroviral therapy on free testosterone levels and fat-free mass in men in a prospective, randomized trial: A5005s, a substudy of AIDS Clinical Trials Group Study 384.

2007

Authors: Dubé MP, Parker RA, Mulligan K, Tebas P, Robbins GK, Roubenoff R, Grinspoon SK

Human pathology

The Y-encoded TSPY protein: a significant marker potentially plays a role in the pathogenesis of testicular germ cell tumors.

2007

Authors: Li Y, Tabatabai ZL, Lee TL, Hatakeyama S, Ohyama C, Chan WY, Looijenga LH, Lau YF

Volume 129 of Issue 23 | Journal of the American Chemical Society

Interfacing silicon nanowires with mammalian cells.

2007

Authors: Kim W, Ng JK, Kunitake ME, Conklin BR, Yang P

Volume 4 of Issue 7 | Nature clinical practice. Oncology

Should recommendations for colorectal-cancer screening be changed?

2007

Authors: Allison JE

Respiratory physiology & neurobiology

Alveolar edema fluid clearance and acute lung injury.

2007

Authors: Berthiaume Y, Matthay MA

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational study.

2007

Authors: Münster P, Marchion D, Bicaku E, Schmitt M, Lee JH, DeConti R, Simon G, Fishman M, Minton S, Garrett C, Chiappori A, Lush R, Sullivan D, Daud A

American journal of physiology. Lung cellular and molecular physiology

Anti-IL-8 autoantibody:IL-8 immune complexes suppress spontaneous apoptosis of neutrophils.

2007

Authors: Fudala R, Krupa A, Matthay MA, Allen TC, Kurdowska AK

Cell

Structural basis for the inhibition of tyrosine kinase activity of ZAP-70.

2007

Authors: Deindl S, Kadlecek TA, Brdicka T, Cao X, Weiss A, Kuriyan J

Health education & behavior : the official publication of the Society for Public Health Education

Seeing in 3-D: examining the reach of diabetes self-management support strategies in a public health care system.

2007

Authors: Schillinger D, Hammer H, Wang F, Palacios J, McLean I, Tang A, Youmans S, Handley M

Volume 2 of Issue 5 | PLoS clinical trials

Artemether-lumefantrine versus dihydroartemisinin-piperaquine for treatment of malaria: a randomized trial.

2007

Authors: Kamya MR, Yeka A, Bukirwa H, Lugemwa M, Rwakimari JB, Staedke SG, Talisuna AO, Greenhouse B, Nosten F, Rosenthal PJ, Wabwire-Mangen F, Dorsey G

View Abstract

OBJECTIVES

To compare the efficacy and safety of artemether-lumefantrine (AL) and dihydroartemisinin-piperaquine (DP) for treating uncomplicated falciparum malaria in Uganda.

DESIGN

Randomized single-blinded clinical trial.

SETTING

Apac, Uganda, an area of very high malaria transmission intensity.

PARTICIPANTS

Children aged 6 mo to 10 y with uncomplicated falciparum malaria.

INTERVENTION

Treatment of malaria with AL or DP, each following standard 3-d dosing regimens.

OUTCOME MEASURES

Risks of recurrent parasitemia at 28 and 42 d, unadjusted and adjusted by genotyping to distinguish recrudescences and new infections.

RESULTS

Of 421 enrolled participants, 417 (99%) completed follow-up. The unadjusted risk of recurrent falciparum parasitemia was significantly lower for participants treated with DP than for those treated with AL after 28 d (11% versus 29%; risk difference [RD] 18%, 95% confidence interval [CI] 11%-26%) and 42 d (43% versus 53%; RD 9.6%, 95% CI 0%-19%) of follow-up. Similarly, the risk of recurrent parasitemia due to possible recrudescence (adjusted by genotyping) was significantly lower for participants treated with DP than for those treated with AL after 28 d (1.9% versus 8.9%; RD 7.0%, 95% CI 2.5%-12%) and 42 d (6.9% versus 16%; RD 9.5%, 95% CI 2.8%-16%). Patients treated with DP had a lower risk of recurrent parasitemia due to non-falciparum species, development of gametocytemia, and higher mean increase in hemoglobin compared to patients treated with AL. Both drugs were well tolerated; serious adverse events were uncommon and unrelated to study drugs.

CONCLUSION

DP was superior to AL for reducing the risk of recurrent parasitemia and gametocytemia, and provided improved hemoglobin recovery. DP thus appears to be a good alternative to AL as first-line treatment of uncomplicated malaria in Uganda. To maximize the benefit of artemisinin-based combination therapy in Africa, treatment should be integrated with aggressive strategies to reduce malaria transmission intensity.

View on PubMed